JP7767428B2 - ポリペプチド及びその使用 - Google Patents
ポリペプチド及びその使用Info
- Publication number
- JP7767428B2 JP7767428B2 JP2023536144A JP2023536144A JP7767428B2 JP 7767428 B2 JP7767428 B2 JP 7767428B2 JP 2023536144 A JP2023536144 A JP 2023536144A JP 2023536144 A JP2023536144 A JP 2023536144A JP 7767428 B2 JP7767428 B2 JP 7767428B2
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- aib
- diacid
- amide
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025182255A JP2026031965A (ja) | 2020-12-16 | 2025-10-29 | ポリペプチド及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125996P | 2020-12-16 | 2020-12-16 | |
| US63/125,996 | 2020-12-16 | ||
| PCT/EP2021/086034 WO2022129254A1 (en) | 2020-12-16 | 2021-12-15 | Polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025182255A Division JP2026031965A (ja) | 2020-12-16 | 2025-10-29 | ポリペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023554046A JP2023554046A (ja) | 2023-12-26 |
| JP2023554046A5 JP2023554046A5 (https=) | 2024-10-24 |
| JP7767428B2 true JP7767428B2 (ja) | 2025-11-11 |
Family
ID=79287870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536144A Active JP7767428B2 (ja) | 2020-12-16 | 2021-12-15 | ポリペプチド及びその使用 |
| JP2025182255A Pending JP2026031965A (ja) | 2020-12-16 | 2025-10-29 | ポリペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025182255A Pending JP2026031965A (ja) | 2020-12-16 | 2025-10-29 | ポリペプチド及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US12371464B2 (https=) |
| EP (2) | EP4736944A2 (https=) |
| JP (2) | JP7767428B2 (https=) |
| KR (1) | KR20230120134A (https=) |
| CN (1) | CN116685599A (https=) |
| AR (1) | AR124391A1 (https=) |
| AU (2) | AU2021399076B2 (https=) |
| CA (1) | CA3204296A1 (https=) |
| CL (1) | CL2023001719A1 (https=) |
| CO (1) | CO2023009066A2 (https=) |
| CR (1) | CR20230311A (https=) |
| EC (1) | ECSP23052600A (https=) |
| IL (1) | IL303578A (https=) |
| MX (1) | MX2023007288A (https=) |
| TW (1) | TW202241933A (https=) |
| WO (1) | WO2022129254A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230311A (es) | 2020-12-16 | 2023-09-01 | Medimmune Ltd | Polipéptidos y usos de los mismos |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| IL322661A (en) * | 2023-02-10 | 2025-10-01 | Hangzhou Sciwind Biosciences Co Ltd | Polypeptide and its history, composition containing them and their use |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| WO2025147628A2 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Dual amylin calcitonin receptor agonists |
| WO2025242620A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Polypeptide combinations and uses thereof |
| WO2026058194A1 (en) | 2024-09-12 | 2026-03-19 | Medimmune Limited | Polypeptide dosage regimens |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100221240A1 (en) | 2004-10-20 | 2010-09-02 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Chemically Modified Peptide Analogs |
| US20200115430A1 (en) | 2018-10-11 | 2020-04-16 | Intarcia Therapeutics, Inc. | Human amylin analog polypeptides and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5252435B2 (ja) * | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー／エス | アミリン誘導体 |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| ES2662501T3 (es) * | 2008-10-21 | 2018-04-06 | Novo Nordisk A/S | Derivados de amilina |
| US9205135B2 (en) * | 2009-09-22 | 2015-12-08 | University Of Miami | Podocyte pH modulation and uses thereof |
| US20140249076A1 (en) | 2011-10-18 | 2014-09-04 | Astrazeneca Pharmaceuticals Lp | Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties |
| CN105849123A (zh) * | 2013-12-13 | 2016-08-10 | 免疫医疗有限公司 | 蛋白酶抗性肽 |
| JP6730278B2 (ja) * | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| WO2020225781A1 (en) * | 2019-05-08 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate amylin agonists and uses thereof |
| CR20230311A (es) | 2020-12-16 | 2023-09-01 | Medimmune Ltd | Polipéptidos y usos de los mismos |
-
2021
- 2021-12-15 CR CR20230311A patent/CR20230311A/es unknown
- 2021-12-15 MX MX2023007288A patent/MX2023007288A/es unknown
- 2021-12-15 IL IL303578A patent/IL303578A/en unknown
- 2021-12-15 CA CA3204296A patent/CA3204296A1/en active Pending
- 2021-12-15 US US17/551,701 patent/US12371464B2/en active Active
- 2021-12-15 EP EP26151626.4A patent/EP4736944A2/en active Pending
- 2021-12-15 KR KR1020237023385A patent/KR20230120134A/ko active Pending
- 2021-12-15 AU AU2021399076A patent/AU2021399076B2/en active Active
- 2021-12-15 US US18/257,756 patent/US20240067693A1/en active Pending
- 2021-12-15 CN CN202180084231.3A patent/CN116685599A/zh active Pending
- 2021-12-15 WO PCT/EP2021/086034 patent/WO2022129254A1/en not_active Ceased
- 2021-12-15 EP EP21839935.0A patent/EP4263586B1/en active Active
- 2021-12-15 JP JP2023536144A patent/JP7767428B2/ja active Active
- 2021-12-16 TW TW110147305A patent/TW202241933A/zh unknown
- 2021-12-16 AR ARP210103535A patent/AR124391A1/es unknown
-
2023
- 2023-06-14 CL CL2023001719A patent/CL2023001719A1/es unknown
- 2023-07-06 CO CONC2023/0009066A patent/CO2023009066A2/es unknown
- 2023-07-12 EC ECSENADI202352600A patent/ECSP23052600A/es unknown
-
2024
- 2024-10-03 AU AU2024227071A patent/AU2024227071A1/en active Pending
-
2025
- 2025-02-12 US US19/052,168 patent/US20250289860A1/en active Pending
- 2025-10-29 JP JP2025182255A patent/JP2026031965A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100221240A1 (en) | 2004-10-20 | 2010-09-02 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Chemically Modified Peptide Analogs |
| US20200115430A1 (en) | 2018-10-11 | 2020-04-16 | Intarcia Therapeutics, Inc. | Human amylin analog polypeptides and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23052600A (es) | 2023-08-31 |
| AU2024227071A1 (en) | 2024-10-24 |
| CO2023009066A2 (es) | 2023-07-10 |
| WO2022129254A1 (en) | 2022-06-23 |
| US20220204580A1 (en) | 2022-06-30 |
| CA3204296A1 (en) | 2022-06-23 |
| TW202241933A (zh) | 2022-11-01 |
| KR20230120134A (ko) | 2023-08-16 |
| JP2023554046A (ja) | 2023-12-26 |
| JP2026031965A (ja) | 2026-02-25 |
| EP4263586B1 (en) | 2026-03-11 |
| AU2021399076B2 (en) | 2024-07-11 |
| US12371464B2 (en) | 2025-07-29 |
| AR124391A1 (es) | 2023-03-22 |
| IL303578A (en) | 2023-08-01 |
| MX2023007288A (es) | 2023-07-03 |
| AU2021399076A9 (en) | 2024-07-18 |
| CL2023001719A1 (es) | 2024-01-26 |
| US20250289860A1 (en) | 2025-09-18 |
| CN116685599A (zh) | 2023-09-01 |
| AU2021399076A1 (en) | 2023-07-27 |
| CR20230311A (es) | 2023-09-01 |
| US20240067693A1 (en) | 2024-02-29 |
| EP4263586A1 (en) | 2023-10-25 |
| EP4736944A2 (en) | 2026-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7767428B2 (ja) | ポリペプチド及びその使用 | |
| US8343914B2 (en) | Fibrillation resistant proteins | |
| JP6121330B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| CN103649115B (zh) | 多肽 | |
| EP2932981B1 (en) | Albumin-binding derivatives of GLP-1 | |
| CN103596583B (zh) | 新型胰高血糖素类似物 | |
| US8501693B2 (en) | Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen | |
| CN102197049B (zh) | 胰岛淀粉样多肽衍生物 | |
| BR112020010244A2 (pt) | análogos de incretina e seus usos | |
| US20110059887A1 (en) | Meal-time insulin analogues of enhanced stability | |
| US20100099601A1 (en) | Fibrillation-resistant insulin and insulin analogues | |
| CN102933598A (zh) | 新型胰高血糖素类似物 | |
| KR20120123443A (ko) | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 | |
| JP2016521253A (ja) | 持続性作用を有するプロドラッグ | |
| CN106687474A (zh) | 新型胰淀素和降钙素受体激动剂 | |
| US20090209469A1 (en) | Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition | |
| US20140128319A1 (en) | Insulin analogues containing penta-fluoro-phenylalanine at position b24 | |
| JP2011525895A (ja) | アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド | |
| EA050089B1 (ru) | Полипептиды и варианты их применения | |
| AU2013237740B2 (en) | Insulin analogues containing penta-fluora-phenyalanine at position B24 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241015 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241015 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20250227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250707 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250930 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251029 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7767428 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |